Related Experiment Video
Updated: May 25, 2026
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Pre-clinical models of renal carcinoma and their utility in drug development
Brenda C Salumbides1, Kristin M Lehet, Georges Ndikuyeze
1Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA.
Abstract:
Significant progress has been made in the treatment of patients with advanced renal cancer. In addition to immunotherapy, there are several potentially distinct therapeutic approaches for targeting molecular pathways. The murine models detailed in this unit are useful for testing rational combination strategies. Moreover, animal models contribute immensely to the understanding of the genetic, epigenetic, and biological aspects of human disease. Compared to humans, rodent models are relatively short-lived and allow for the facile study of clinically relevant pathologies. Animal models for the study of renal cell carcinoma (RCC) are particularly useful for the development of new drugs for kidney cancer. Included in this unit are several in vivo models that are currently used to evaluate therapeutic approaches to renal cancer therapy and to investigate the pathophysiology of this condition. Included are both murine (RENCA) and renal cell carcinomas in subcutaneous and orthotopic models using tumor cell lines and human tumor tissue.
Insights
Murine models advance kidney cancer research by enabling the study of renal cell carcinoma (RCC) and testing new combination therapies for improved patient treatment.
Area of Science:
- Oncology
- Translational Medicine
- Animal Models
Background:
- Advanced renal cancer treatment has seen significant progress with immunotherapy and targeted molecular pathway therapies.
- Animal models are crucial for understanding the genetic and biological aspects of human diseases like kidney cancer.
Purpose of the Study:
- To detail murine models for evaluating combination therapeutic strategies in advanced renal cancer.
- To highlight the utility of animal models in advancing kidney cancer drug development and understanding disease pathophysiology.
Main Methods:
- Utilizing established in vivo models, including murine (RENCA) and renal cell carcinoma models.
- Employing both subcutaneous and orthotopic models with tumor cell lines and human tumor tissue.
- Leveraging the short lifespan and study of clinically relevant pathologies in rodent models.
Main Results:
- Demonstrated the utility of murine models for testing novel combination therapies.
- Provided insights into the genetic, epigenetic, and biological underpinnings of renal cell carcinoma.
- Facilitated the evaluation of therapeutic approaches for renal cancer.
Conclusions:
- Murine models are invaluable for advancing renal cell carcinoma research and drug development.
- Animal models significantly contribute to understanding kidney cancer pathophysiology.
- These models support the investigation of rational combination strategies for treating advanced renal cancer.
